Supporting healthcare professionals in their efforts to maintain and improve their knowledge, ability, and performance related to treating patients with mBC is critical to improving patient care. The quality of care that healthcare professionals provide takes place in complex systems that are often in need of analysis and modification to allow for more efficient and effective patient care. In addition, providing resources and education to patients, their caregivers, and family members is crucial to help ensure they are informed and can participate in the shared decision-making process.

Rethink and Pfizer are committed to funding projects that:

•  Encourage the use of multi-disciplinary care models (e.g. nurse navigators, palliative care, psychological/mental health support)
• Address disparities in mBC related care for those marginalized due to age, race, income or other factors (equity, diversity, inclusion, accessibility)
• Use real world evidence to improve quality of care for mBC patients
• Facilitate healthcare systems and providers to engage patients, their caregivers and families in shared decisionmaking
• Optimize patient care by improving access to precision medicine and/or alternative diagnostic tools (e.g., liquid biopsy), and throughout the patient cancer experience, including access to clinical trials and evidence-based treatment.
• Include metastatic breast cancer patients as members of the research team where their perspectives and involvement will be valued
• Provide sustainable solutions that both improve quality of care for mBC patients and optimally can be utilized or easily implemented in a host of other settings

Multiple factors contribute to the complexity of treating the disease including:

• The need for cross-functional involvement in care
• The rapidly changing options for personalizing treatment strategies, including access to precision medicine and alternative diagnostic tools
• Managing treatment and disease side effects
• Communicating with patients, caregivers and family members about quality of life and end-of-life decisions and other obstacles patients face when living with the disease.

For topics of interest for this RFP, see https://cdn.pfizer.com/pfizercom/2023-01/RFP%20RETHINK%20BC%20Pfizer%20-%20English.pdf?I3kNTsX_rTk2tg7B740MxqU_qr2r75P5#page=4

Estimated Total Program Funding: